Table 2.
Cox proportional regression analysis for the prediction of nasopharyngeal patient OS and DFS
| Univariate analysis |
||||
|---|---|---|---|---|
| OS |
DFS |
|||
| Covariant | HR (95% CI) | p | HR (95% CI) | `p |
| Age (< 50 vs. ≥ 50) | 0.768 (0.494–1.194) | 0.241 | 0.742 (0.489–1.128) | 0.162 |
| Gender (Female vs. Male) | 0.863 (0.534–1.394) | 0.547 | 0.798 (0.509–1.251) | 0.326 |
| T classification (T1 vs. T2 vs. T3 vs.T4) | 1.774 (1.372–2.294) | < 0.001 | 1.765 (1.381–2.256) | < 0.001 |
| N classification (N0 vs. N1 vs. N2 vs. N3) | 1.660 (1.302–2.117) | < 0.001 | 1.686 (1.339–2.123) | < 0.001 |
| M classification (M0 vs. M1) | 2.783 (1.769–4.379) | < 0.001 | 2.660 (1.715–4.125) | < 0.001 |
| Clinical stage (I vs. II vs. III vs. IV) | 3.106 (1.679–5.746) | < 0.001 | 2.339 (1.742–3.141) | < 0.001 |
| Histological differentiation (U vs. D) | 1.727 (0.969–3.078) | 0.064 | 1.481 (0.882–2.489) | 0.138 |
| Treatment (1 vs. 2 vs. 3) | 0.571 (0.424–0.770) | < 0.001 | 0.565 (0.425–0.750) | < 0.001 |
| CD3 in total (High vs. Low) | 0.741 (0.475–1.156) | 0.186 | 0.730 (0.479–1.112) | 0.143 |
| Intratumoral CD3 (High vs. Low) | 0.545 (0.346–0.859) | 0.009 | 0.522 (0.339–0.804) | 0.003 |
| Peritumoral CD3 (High vs. Low) | 1.141 (0.734–1.774) | 0.559 | 1.094 (0.720–1.662) | 0.673 |
| ICs-PD-L1 (Postive vs. Negative) | 0.585 (0.309–1.106) | 0.099 | 0.571 (0.311–1.051) | 0.072 |
| TCs-PD-L1 (Postive vs. Negative) | 0.563 (0.335–0.945) | 0.030 | 0.597 (0.369–0.964) | 0.035 |
| Type in total CD3 (I vs. II vs. III vs. IV) | 1.143 (0.942–1.386) | 0.176 | 1.122 (0.934–1.348) | 0.220 |
| Type in intratumoral CD3 (I vs. II vs. III vs. IV) | 1.220 (1.008–1.478) | 0.041 | 1.180 (0.983–1.416) | 0.046 |
| Multivariate analysis |
||||
| OS |
DFS |
|||
| Covariant | HR (95% CI) | p | HR (95% CI) | p |
| T classification (T1 vs. T2 vs. T3 vs.T4) | 1.121 (0.820–1.531) | 0.475 | 1.113 (0.810–1.528) | 0.509 |
| N classification (N0 vs. N1 vs. N2 vs. N3) | 1.048 (0.772–1.422) | 0.763 | 0.982 (0.714–1.351) | 0.912 |
| M classification (M0 vs. M1) | 0.756 (0.377–1.516) | 0.431 | 0.673 (0.318–1.425) | 0.301 |
| Clinical stage (I vs. II vs. III vs. IV) | 2.412 (1.270–4.582) | 0.007 | 2.823 (1.417–5.625) | 0.003 |
| Treatment (1 vs. 2 vs. 3) | 0.447 (0.321–0.622) | < 0.001 | 0.444 (0.314–0.629) | < 0.001 |
| Intratumoral CD3 (High vs. Low) | 0.607 (0.371–0.995) | 0.084 | 0.624 (0.366–1.063) | 0.083 |
| TCs-PD-L1 (Postive vs. Negative) | 1.116 (0.647–1.924) | 0.693 | 1.037 (0.583–1.845) | 0.900 |
| Type in intratumoral CD3 (I vs. II vs. III vs. IV) | 1.387 (1.074–1.790) | 0.012 | 1.465 (1.113–1.928) | 0.006 |
TCs-PD-L1, Tumor Cells Programmed death ligand 1; ICs-PD-L1, Immune Cells Programmed death ligand 1.